Sanofi’s pediatric vaccine “Hexaxim” is the most administered hexavalent vaccine in the world with 63% of volume share
A new study provides detailed insights into the usage patterns of pediatric aP hexavalent vaccines, the volumes administered by country and region, and the leading manufacturers. The report examines 102 countries in which hexavalent brands were registered in 2018.
Hexavalent vaccines benefit both infants and governments.
Hexavalent vaccines are six in-one (or 5+1) combination vaccines recommended for administration in three or four doses to protect babies under one year old against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, haemophilus influenza type B and hepatitis B.
By including six antigens in a single dose, hexavalent vaccines increase the coverage rate, ensure access to inactivated polio vaccine (IPV), lower the risk of delayed or missed vaccinations and reduce the complications associated with multiple intramuscular injections. They also decrease stocking and administration costs.
35 million doses of hexavalent vaccine administered in 2018
In 2018, the top 25 countries consumed 30 million doses of hexavalent vaccines which is 86% of the hexavalent vaccine global consumption
The vaccines come in two main forms: DTwP vaccines, which have a whole-cell pertussis component; and DTaP vaccines, which include two or more acellular pertussis components. Whilst more expensive, aP vaccines have been developed to address the adverse reactions sometimes seen with whole-cell vaccines. Despite this, DTwP vaccines remain more widely used and represented 83% or 380 million of the doses administered in 2018.
The market for DTaP vaccines is now shifting decisively towards hexavalent variants; this is especially true in European and other high income countries, where their significant benefits have led to them securing preferred status. Of the 75m doses of DTaP vaccine consumed in 2018, 35m or 47% were hexavalent.
The top 25 countries by usage of hexavalent vaccines represented 86% of global consumption (30m doses). The countries are geographically diverse: Iraq, South Africa and Mexico each consumed more than 3m doses; with Germany, the UK, and France each consuming more than 2m doses. Overall, Europe accounted for 44% of the hexavalent vaccines market by volume.
Globally, Hexaxim is the leader in hexavalent vaccines
There are three brands of pediatric hexavalent vaccine commercially available: Hexaxim/Hexyon/ Hexacima (manufactured by Sanofi Pasteur); Infanrix Hexa (Glaxosmithkline, GSK); and Vaxelis (MCM). In 2018, Hexaxim was the clear market leader by global volume with 63% (approximately 19m doses), followed by Infanrix Hexa with 33%, and Vaxelis with 4%.
In public markets (those where the Government bears part or all of the cost of immunisation), Hexaxim had an even higher share of 69.6%. Hexaxim is the only brand used in the national immunisation schedule in eight public markets: Iraq, Mexico, South Africa, Saudi Arabia, Libya, Kazakhstan, Belgium, and Chile. Half a million preterm babies (babies born alive before 37 weeks of pregnancy) in these countries were administered with Hexaxim vaccine in 2018.
Fully liquid and ready-to-use, Hexaxim is the only hexavalent vaccine that has World Health Organisation prequalification status; and is also the only one available in both pre-filled syringes or mono-dose vials.
Find out more about hexavalent vaccines.
A White Paper To Understand The Market Structure of Pediatric Pertussis Combination Vaccines contains rich data on the usage of hexavalent and other DTB-based multivalent vaccines around the world. To download your copy, click here.